Prognostic Value and Reproducibility of Pretreatment CT Texture Features in Stage III Non-Small Cell Lung Cancer

被引:155
作者
Fried, David V. [1 ,2 ]
Tucker, Susan L. [5 ]
Zhou, Shouhao [3 ]
Liao, Zhongxing [4 ]
Mawlawi, Osama [2 ]
Ibbott, Geoffrey [1 ,2 ]
Court, Laurence E. [1 ,2 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Radiat Phys, Houston, TX 77030 USA
[2] Univ Texas Hlth Sci Ctr Houston, Grad Sch Biomed Sci, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Div Quantitat Sci, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2014年 / 90卷 / 04期
关键词
TUMOR HETEROGENEITY; SURVIVAL; DISCUSSIONS; TOMOGRAPHY; PHYSICIANS; RADIATION;
D O I
10.1016/j.ijrobp.2014.07.020
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To determine whether pretreatment CT texture features can improve patient risk stratification beyond conventional prognostic factors (CPFs) in stage III non-small cell lung cancer (NSCLC). Methods and Materials: We retrospectively reviewed 91 cases with stage III NSCLC treated with definitive chemoradiation therapy. All patients underwent pretreatment diagnostic contrast enhanced computed tomography (CE-CT) followed by 4-dimensional CT (4D-CT) for treatment simulation. We used the average-CT and expiratory (T50-CT) images from the 4D-CT along with the CE-CT for texture extraction. Histogram, gradient, co-occurrence, gray tone difference, and filtration-based techniques were used for texture feature extraction. Penalized Cox regression implementing cross-validation was used for covariate selection and modeling. Models incorporating texture features from the 33 image types and CPFs were compared to those with models incorporating CPFs alone for overall survival (OS), local-regional control (LRC), and freedom from distant metastases (FFDM). Predictive Kaplan-Meier curves were generated using leave-one-out cross-validation. Patients were stratified based on whether their predicted outcome was above or below the median. Reproducibility of texture features was evaluated using test-retest scans from independent patients and quantified using concordance correlation coefficients (CCC). We compared models incorporating the reproducibility seen on test-retest scans to our original models and determined the classification reproducibility. Results: Models incorporating both texture features and CPFs demonstrated a significant improvement in risk stratification compared to models using CPFs alone for OS (P = .046), LRC (P = .01), and FFDM (P = .005). The average CCCs were 0.89, 0.91, and 0.67 for texture features extracted from the average-CT, T50-CT, and CE-CT, respectively. Incorporating reproducibility within our models yielded 80.4% (+/- 3.7% SD), 78.3% (+/- 4.0% SD), and 78.8% (+/- 3.9% SD) classification reproducibility in terms of OS, LRC, and FFDM, respectively. Conclusions: Pretreatment tumor texture may provide prognostic information beyond that obtained from CPFs. Models incorporating feature reproducibility achieved classification rates of similar to 80%. External validation would be required to establish texture as a prognostic factor. (C) 2014 Elsevier Inc.
引用
收藏
页码:834 / 842
页数:9
相关论文
共 50 条
  • [31] Prognostic Value of Pretreatment Lymphocyte-to-Monocyte Ratio in Non-Small Cell Lung Cancer: A Meta-Analysis
    Wang, Yan
    Huang, Dong
    Xu, Wen-Ying
    Wang, Yan-Wen
    Che, Guo-Wei
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (10) : 523 - 530
  • [32] Prognostic value of various metabolic parameters on pre-treatment 18F-FDG PET/CT in patients with stage I-III non-small cell lung cancer
    Demir, F.
    Yanarates, A.
    [J]. INTERNATIONAL JOURNAL OF RADIATION RESEARCH, 2020, 18 (04): : 799 - 807
  • [33] How to use CT texture analysis for prognostication of non-small cell lung cancer
    Miles, Kenneth A.
    [J]. CANCER IMAGING, 2016, 16
  • [34] Texture Analysis of Non-Small Cell Lung Cancer on Unenhanced CT and Blood Flow Maps: a Potential Prognostic Tool
    Baiocco, Serena
    Barone, Domenico
    Gavelli, Giampaolo
    Bevilacqua, Alessandro
    [J]. PROCEEDINGS OF THE 24TH CONFERENCE OF OPEN INNOVATIONS ASSOCIATION (FRUCT), 2019, : 31 - 39
  • [35] Value of the Glasgow Prognostic Score as a Prognostic Factor in Resectable Non-Small Cell Lung Cancer
    Yotsukura, Masaya
    Ohtsuka, Takashi
    Kaseda, Kaoru
    Kamiyama, Ikuo
    Hayashi, Yuichiro
    Asamura, Hisao
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (08) : 1311 - 1318
  • [36] Prognostic value of pretherapeutic FDG PET/CT in non-small cell lung cancer with pulmonary lymphangitic carcinomatosis
    Park, Yong-Jin
    Im, Yunjoo
    Kwon, O. Jung
    Han, Joungho
    Ahn, Myung-Ju
    Kim, Jhingook
    Um, Sang-Won
    Choi, Joon Young
    [J]. SCIENTIFIC REPORTS, 2023, 13 (01)
  • [37] Prognostic value of PD-L1 expression in patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy
    Vrankar, Martina
    Kern, Izidor
    Stanic, Karmen
    [J]. RADIATION ONCOLOGY, 2020, 15 (01)
  • [38] Prognostic stratification using F-18 FDG PET/CT in patients with advanced stage (Stage III and IV) non-small cell lung cancer
    Kim, Y. S.
    Lee, M. K.
    Kim, S. J.
    Kim, I. J.
    Kim, Y. K.
    Jo, W. S.
    Park, S. K.
    [J]. NEOPLASMA, 2010, 57 (03) : 241 - 246
  • [39] Prognostic Value of Semiautomatic CT Volumetry in Patients With Stage I Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy
    Satoh, Yoko
    Motosugi, Utaroh
    Nambu, Atsushi
    Saito, Akitoshi
    Onishi, Hiroshi
    [J]. JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 2016, 40 (03) : 343 - 350
  • [40] Chemoradiotherapy efficacy in patients with stage III non-small cell lung cancer (NSCLC): A prognostic clinical and biomarker-based model
    Vaes, Rianne D. W.
    Cortiula, Francesco
    Lyu, Shaowen
    Hiltermann, T. Jeroen N.
    Houben, Ruud
    Degens, Juliette
    Hendriks, Lizza E. L.
    De Ruysscher, Dirk
    [J]. LUNG CANCER, 2025, 203